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Circulating tumor DNA (ctDNA) is an emerging field of cancer research. For lung
cancer, non-invasive genotyping of EGFR is the foremost application. The activat-
ing mutations represent the ctDNA from all cancer cells, and the T790M-resistant
mutation represents that from resistant cells. We examined the ctDNA dynamics
of EGFR mutations by using deep sequencing with a massively parallel DNA
sequencer. We obtained 190 plasma samples from 57 patients at various times
during the treatment course and classified them according to treatment status.
The mutation detection rate of exon 19 deletion ⁄ L858R in plasma was high at
the initiation of treatment with epidermal growth factor receptor tyrosine kinase
inhibitor (EGFR-TKI; P = 0.001), suppressed during EGFR-TKI treatment before dis-
ease progression, and elevated after the onset of disease progression (P = 0.023).
The mutation detection rate of T790M was low until the onset of disease pro-
gression and elevated thereafter (P = 0.01). Samples across the development of
disease progression were obtained from 10 patients and showed a correlation
between increased ctDNA level and disease progression. Decreased ctDNA level
in response to the initiation of EGFR-TKI was observed in 4 of 6 eligible patients.
In two patients, the ctDNA dynamics suggested the presence of cancer cell popu-
lations only with the T790M mutation. In another patient, the T790M ctDNA rep-
resented cell subpopulations that respond to cytotoxic agents differently from
the major population. Considering the high incidence, ctDNA could be a clinical
parameter to complement information from image analyses.
C irculating tumor DNA (ctDNA) is the cell-free DNAreleased from dying cancer cells into the bloodstream(1)
and is an emerging field in cancer research. Clinical applica-
tions of ctDNA are expected to be in the form of “liquid
biopsy”,(2) allowing for the replacement of tissue biopsy with
non-invasive blood tests. Circulating tumor DNA is a carrier
that brings the genetic information of solid tumors to periph-
eral blood. In addition, the quantitative ctDNA levels are gen-
erally considered to correlate with tumor burden. These
characteristics are the basis of its clinical applications.
In the case of lung cancer, due to the strong correlation
between EGFR activating mutations and the efficacy of epi-
dermal growth factor receptor tyrosine kinase inhibitors
(EGFR-TKIs),(3,4) detection of the mutations is indispensable
for therapeutic decision making. Since the discovery of the
correlation, the use of ctDNA has been extensively investi-
gated for genotyping of EGFR. The recent introduction of
next-generation EGFR-TKIs(5,6) targeted to the EGFR with a
resistant mutation, that is, T790M,(7) raises the need of geno-
typing after the onset of disease progression, which will con-
siderably benefit from the use of ctDNA.
Another application of ctDNA is the monitoring of disease
progression(8) and drug resistance.(9–11) From a technical view-
point, this type of application requires quantitation of ctDNA
and use of digital PCR(12) or related technologies such as next-
generation sequencing is indispensable. In EGFR-TKI treat-
ment, activating and resistant mutations can be used as inde-
pendent parameters, with activating mutation for the ctDNA
from all cancer cells and resistant mutation (T790M) for the
ctDNA from cells resistant to EGFR-TKI.
We constructed a detection system for EGFR mutations in
ctDNA by using deep sequencing with a massively parallel
DNA sequencer.(13) This system is one of the most intensively
validated assay systems for ctDNA.(14) In this report, we used
clinical evaluation based on the Response Evaluation Criteria
in Solid Tumors (RECIST)(15) as a reference and examined
ctDNA dynamics represented by activating and resistant muta-
tions using the detection system.
© 2015 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd
on behalf of Japanese Cancer Association.
This is an open access article under the terms of the Creative Commons
Attribution-NonCommercial-NoDerivs License, which permits use and distribution
in any medium, provided the original work is properly cited, the use is non-
commercial and no modifications or adaptations are made.
Cancer Sci | March 2016 | vol. 107 | no. 3 | 353–358
Materials and Methods
Patient description. Lung cancer patients subjected to EGFR-
TKI treatment or with a history of EGFR-TKI treatment were
recruited in this study. Patients whose data were used as refer-
ence, that is, the data obtained in the multi-institute study(14)
for the assessment of the detection system, were recruited as
previously described. Written informed consent was obtained
from all of the participants. This study was approved by the
ethics committee of the Osaka Medical Center for Cancer and
Cardiovascular Diseases (Osaka, Japan).
Blood sampling and DNA preparation. Blood samples were
collected between October 2010 and August 2013. Approxi-
mately 5 mL blood was taken from each patient, with EDTA
as anticoagulant. Plasma was separated from the blood cells
using low-speed centrifugation. The plasma was transferred to
a fresh tube and recentrifuged at 15 100 g for 10 min at room
temperature and stored at 80°C until DNA extraction. Cell-
free DNA was purified as previously described.(13)
Clinical evaluation of disease progression. Evaluation of
response to EGFR-TKI treatment was carried out based on
RECIST version 1.1,(15) approximately 2 months after the initi-
ation of EGFR-TKI. Evaluation of disease progression during
the EGFR-TKI treatment was also based on the RECIST crite-
ria. Additional criteria recommended in the Guideline for
Treatment and Diagnosis of Lung Cancer (http://www.hai-
gan.gr.jp/modules/guideline) were also applied.
Mutation detection system. The detection system searches
mutations by deep sequencing, that is, sequencing a large num-
ber of gene fragments. Exons 19, 20, and 21 of the EGFR
gene were independently amplified with PCR from patient
plasma DNA, and deep sequencing was undertaken with the
Ion Torrent PGM (Thermo Fisher Scientific, Waltham, MA,
USA).(16) More than 100 000 reads were obtained for each
exon region. Because each read was of a single molecule, we
were able to estimate the relative ratio of mutation alleles from
the fraction of reads containing deletions ⁄ substitutions. A diag-
nostic score, termed the plasma mutation (PM) score, was
defined as the number of reads with deletions (exon 19 dele-
tions) or substitutions (exon 20, T790M; exon 21, L858R,
L861Q) in 100 000 reads. Thresholds for mutation detection
were set as previously described.(13,14)
The laboratory procedures of the mutation detection were
the same as previously described,(13) except for the use of the
latest versions of sequencing reagents at the time of assay. The
assay was carried out on samples from various projects in
order of arrival at the laboratory. The initial PCR amplification
of EGFR exon fragments was successful in all of the samples,
and mutation data were obtained from all the samples.
Results
Description of sample population. The samples were obtained
from 57 patients at various times during their treatment course.
The clinical characteristics of the patient population are sum-
marized in Table 1. The number of samples from a single
patient ranged from 5 to 13 samples in 16 patients, from 2 to 4
in 15 patients, and 1 in 26 patients. In total, 190 plasma DNA
samples were obtained. Circulating tumor DNA data of 139
samples were used in the previous study.(13) All clinical infor-
mation was refined and updated for the following analysis.
Analysis of plasma sample population. Data of all the 190
plasma samples, used as the analysis set, were pooled and sub-
jected to the following analyses. We first compared the analy-
sis set with the dataset obtained from the multi-institute
prospective study(14) as the reference set. The patient popula-
tion of the latter set is a uniform population for comparison of
genotyping of plasma and biopsy samples. The numbers of
samples that were mutation-positive in plasma were grouped
according to abundance (PM score range) in Table 2. To com-
pare with the reference set, we focused on samples whose cor-
responding biopsy samples had exon 19 deletion or L858R for
analysis of activating mutations. For T790M, all of the sam-
ples were used. The mutation detection rate in plasma was
considerably lower in the analysis set. Samples with low PM
scores were more frequent in the analysis set.
The samples of the analysis set may be classified into the
following five categories: EGFR-TKI treatment initiation (TKI
initiation); EGFR-TKI treatment before development of objec-
tive disease progression (non-PD); EGFR-TKI treatment with
objective disease progression (PD); treatment other than
EGFR-TKI; and discontinued EGFR-TKI treatment. The num-
bers of samples in the latter two groups were too small
(n = 13 and 9, respectively) for a proper statistical analysis.
Table 1. Characteristics of patients with lung cancer treated with
















Squamous cell carcinoma 1
Adenocarcinoma 56
Mutation in biopsy samples






Type of EGFR-TKI treatment
Gefitinib 28
Erlotinib 13
Gefitinib ? erlotinib 9
Erlotinib ? gefitinib 1
Erlotinib + bevacizumab 2
Erlotinib + gemcitabine 2
Cytotoxic agents 2
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The samples of TKI initiation were set as those before EGFR-
TKI treatment and those until 2 weeks after the initiation of
the treatment based on previous observations.(13) The samples
of the first three categories are shown in the top sections of
Table 3. Activating and T790M-resistant mutations shared the
same features with the non-PD and PD samples: the mutation
detection rate in plasma was low with non-PD samples, and
high with PD. To assess the significance of the difference in
the mutation detection rates in the sample population against
the variance between samples in the groups (non-PD or PD),
we used median values as the representative statistic for each
group (non-PD or PD) in each patient, determined as positive ⁄
negative in plasma (the bottom sections of Table 3), and calcu-
lated P-values by using the Fisher’s exact test. The statistical
significance of exon 19 deletion ⁄L858R and T790M were
P = 0.023 and P = 0.010, respectively. We also applied this
analysis for comparison of TKI initiation and non-PD. The
statistical significance of exon 19 deletion ⁄L858R and that of
T790M were P = 0.001 and P = 1.000, respectively. Thus, the
mutation detection rate of exon 19 deletion ⁄L858R in plasma
was high in the initiation of EGFR-TKI treatment, suppressed
during EGFR-TKI treatment before disease progression, and
elevated after development of disease progression. The muta-
tion detection rate of T790M was low until the onset of objec-
tive disease progression and elevated thereafter.
We compared the distributions of the PM scores with the
non-PD and PD “mutation-positive in plasma” samples
(Fig. 1). The PD samples tended to be distributed in fractions
of high PM scores compared with non-PD samples.
Temporal changes in ctDNA represented by the activating
mutations. We then confirmed the above results with the
dynamics of individual patients. Six patients, patients 1–3 and
6–8, had samples in TKI initiation, non-PD, and PD. Another
four patients, patients 4–5 and 9–10, had samples in non-PD
and PD (Figs 2,S1). The clinical information of the patients
including details of objective disease progression is summa-
rized in Table S1.
First, we examined the dynamics of the activating mutations.
The activating mutations were detected, except patient 4
(Fig. 2d). Patients 1–3 represented the typical pattern (Fig. 2a–
c). Before the initiation of EGFR-TKI, the ctDNA level of the
activating mutations was high, but after the initiation of
EGFR-TKI, the level decreased. Other patients also showed
dynamics concordant to the results of the above-mentioned
analysis of the sample population. In patient 1, the dynamic
pattern of carcinoembryonic antigen (CEA) was similar to that
of ctDNA. However, in patients 2 and 3, CEA showed an ini-
tial decrease in response to EGFR-TKI but did not show an
increase reflecting disease progression.






















<100 0 1 6 7 5
100–999 6 10 26 17 18
1000–9999 11 7 7 16 7
>10 000 8 5 7 7 2
Total 25 23 46 47 32
All samples
Total 36 30 83 92 190
Detection rate
in plasma, %
69.4 76.7 55.4 51.1 16.8
Analysis set comprised 190 plasma samples from 57 patients taken
during their treatment course. The reference dataset was obtained
from a multi-institute prospective study(14) that comprised a uniform
population for comparison of genotyping of plasma and biopsy sam-
ples. The plasma-positive samples were grouped according to PM
score range.
Table 3. Numbers of plasma samples or cases from patients with
lung cancer in each treatment status category
TKI initiation Non-PD PD
Exon 19 deletion or L858R
Plasma-positive samples 18 32 31
All samples 24 92 41
Detection rate in plasma, % 75.0 34.8 75.6
T790M
Plasma-positive samples 2 15 14
All samples 29 94 54
Detection rate in plasma, % 6.9 16.0 25.9
Exon 19 deletion or L858R
Plasma-positive cases 13 7 12
Plasma-negative cases 2 16 5
T790M
Plasma-positive cases 1 2 8
Plasma-negative cases 15 22 10
PD, disease progression; TKI, tyrosine kinase inhibitor.
(a)
(b)
Fig. 1. Distribution of plasma mutation (PM) scores of the “muta-
tion-positive in plasma” samples from lung cancer patients. Vertical
axis, fraction of samples (%) within the PM score range; horizontal
axis, PM score range; black bar, non-disease progression samples;
white bar, disease progression samples. (a) Exon 19 deletion ⁄ L858R.
(b) T790M.
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On the whole, the increase in ctDNA level represented by
the activating mutations at the onset of objective disease pro-
gression was observed in 9 of 10 patients. Including patient 4,
whose T790M ctDNA exhibited the same pattern, all 10
patients showed increased ctDNA levels. By contrast,
increased CEA level was present in only 4 (40%) of 10
patients. Decreased ctDNA at the initiation of EGFR-TKI was
observed in 4 (67%) of 6 patients eligible for analysis. In this
timing, decreased CEA level was observed in 6 (60%) of 10
patients.
Temporal changes in ctDNA represented by the T790M-resis-
tant mutation. We then examined the ctDNA dynamics repre-
sented by the T790M-resistant mutation. In general, as
indicated by the above analysis of the sample population, the
ctDNA level of T790M increased in response to disease pro-
gression but was consistently smaller than that of the activat-
ing mutations (patients 1, 3, 9, and 10; Figs 2a,c,S1d,e). The
T790M ctDNA level indicated the fraction of the mutation
allele or cancer cells with the resistant mutation.
Patients 3 and 4 (Fig. 2c,d) had positive data points only
with T790M, suggesting the presence of cancer cell popula-
tions carrying the T790M mutation but no activating muta-
tions. In patient 3, the T790M ctDNA appeared transiently
during the non-PD period. In patient 4, the T790M ctDNA
appeared in parallel with disease progression. Because the pri-
mary lesion of patient 4 had exon 19 deletion, EGFR-TKI
would have eliminated the original cancer cell population and
a unique cell population with T790M only would have
appeared in PD. Otherwise, alleles with exon 19 deletion
would have been lost during the treatment.
Patient 5 (Fig. 2e) had a considerable number of samples in
PD. After the initial onset of disease progression, ctDNA
appeared. During therapy with cytotoxic agents, the T790M
ctDNA was suppressed, but the activating mutation was con-
stantly increased. This suggests that cytotoxic agents success-
fully suppressed the T790M-positive cell populations, but the
agents could not control the growth of other cancer cells with
the activating mutation. A subsequent rechallenge of EGFR-
TKI suppressed the ctDNA level with the activating mutation
and without T790M, reflecting a transient improvement in dis-
ease status. The dynamic pattern of ctDNA coincided with the
treatment status and may explain the mechanism of successful
rechallenge.
The results of the multi-institute study for the assessment of
diagnostic accuracy(14) indicated that the possibility of false-
positive results was negligible for data points with PM scores
exceeding 300 (limit of quantitation [LOQ]). False-positive rates
for exon 19 deletion, L858R, and T790M were estimated as 2%,
0%, and 1%, respectively, from the diagnostic specificities cal-
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Fig. 2. Circulating tumor DNA dynamics in the
course of epidermal growth factor receptor tyrosine
kinase inhibitor treatment of lung cancer patients.
Vertical axis, plasma mutation score (exon 19
deletion, L858R, and T790M) or protein
concentration (carcinoembryonic antigen [CEA], lg ⁄
mL). Horizontal axis, days from initiation of
treatment. The horizontal lines at the top of each
panel indicate treatment: vertical bar, initiation of
therapy; arrowhead, termination of therapy. Gray
arrows below the horizontal lines indicate
radiotherapy. Arrowheads in the bottom of each
panel indicate disease progression time points. Blue
lines indicate activating mutations (exon 19
deletion or L858R). Red lines indicate T790M. Black
broken lines indicate CEA. In the patients who had
no data exceeding the threshold of detection
(plasma mutation score) or whose data were within
the normal range (CEA), data were not presented
in graphs. (a) Patient 1, female, aged 65 years, with
stage IV disease. (b) Patient 2, female, aged
71 years, with stage IV disease. (c) Patient 3, male,
aged 68 years, with stage IV disease. (d) Patient 4,
male, aged 76 years, with stage IV disease. (e)
Patient 5, female, aged 59 years, with stage IV
disease.
© 2015 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd
on behalf of Japanese Cancer Association.
Cancer Sci | March 2016 | vol. 107 | no. 3 | 356
Original Article
Dynamics of circulating tumor DNA www.wileyonlinelibrary.com/journal/cas
a comparator. These figures are the maximum estimates, and
the real figures would have been lower because the calcula-
tion of the specificities assumed that the biopsy samples had
no false negatives. All data points relevant for the above-
mentioned cases sufficed the criterion: their PM scores
exceeded the LOQ. Because the PM score of the T790M
ctDNA at day 216 of patient 2 did not exceed the LOQ
(Fig. 2b), it was retained to judge it as a distinct cancer cell
population. Owing to the high reproducibility of data points
over the LOQ,(13) the possibility of false negatives of the
data points potentially over the LOQ is also negligible.
Discussion
In our series of studies on non-invasive genotyping of EGFR,
we prioritized the validation of the detection system, perform-
ing a multi-institute prospective study.(14) We then proceeded
to analyze other datasets referring to the performance revealed
by the study. Our ctDNA data provide firm confidence, elimi-
nating the need for parallel experiments such as analysis of
biopsy samples.
Most studies on ctDNA dynamics have been restricted to the
analysis of individual patients, and statistical analysis of a pop-
ulation is sparse. We showed a statistically significant differ-
ence in the mutation detection rate in plasma samples between
the disease and treatment conditions. The ctDNA dynamics of
individual patients were generally consistent with the results of
the analysis of the sample population and showed that ctDNA
is a possible clinical parameter to complement image analysis.
A major characteristic of ctDNA dynamics is a wider dynamic
range of responses compared to the serum biomarker CEA.
From a scientific viewpoint, identification of the T790M
ctDNA representing distinct cancer cell subpopulations is par-
ticularly interesting. We observed this phenomenon in another
prospectively collected dataset (manuscript in preparation).
Another study that used a different technique also observed
this phenomenon.(17)
The PM score represents the relative ratio of ctDNA to
plasma cell-free DNA. Other studies, for example, a study
using droplet digital PCR carried out by Oxnard et al.,(18)
have used the absolute amount of ctDNA rather than the rel-
ative ratio. Currently, both parameters are likely to exhibit
good correlation with the disease status. However, processing
raw data for medical interpretation is an important component
of technologies, and a detailed comparison might be
necessary.
In two patients, the ctDNA dynamics suggested the presence
of cancer cell populations only with the T790M mutation.
Investigation of their origin is interesting, but there are two
concerns. Circulating tumor DNA is considered as a correlate
of tumor burden, but it is not necessarily true, as the direct
correlation is with dying cancer cells. Thus, for example, when
cells with high turnover rate yield more ctDNA than those
with low turnover rate, their population sizes might not be par-
allel with ctDNA levels. Another concern is technical. Such
cells would exist as a minor population in tumor tissues, and
their detection is technically demanding. The most refined
experiment on EGFR so far collected 50 cells for each sam-
ple.(19) Recent developments of single cell genomics have
enabled genotyping of single cells, which would provide accu-
rate information.
Monitoring of acquired resistance has considerable clinical
benefits. Several agents have resistant mutations that can serve
as markers to detect ctDNA. Studies on the dynamics were
reported with anti-EGFR antibodies and aromatase inhibitors,
as well as EGFR-TKI using mutations of KRAS,(9,10) ESR1,(20)
and EGFR,(11,13,18) respectively. In EGFR-TKI treatment, the
activating and T790M-resistant mutations can be used as inde-
pendent parameters. In the case of the other agents, usually
only resistant mutations were used because additional proce-
dures are required to identify marker mutations for the entire
cancer cell population. As indicated above, in most cases, the
activating mutations served as a better marker for disease pro-
gression owing to acquired resistance. The merit of the T790M
ctDNA may be, besides that it is a direct cause of resistance,
that it represents cell subpopulations that respond to therapies
differently from the major populations. A similar example was
reported with rociletinib.(21)
Several new EGFR-TKIs targeted to T790M such as
AZD9291(5) and rociletinib(6) are emerging, and their use
requires detection of T790M. Because rebiopsy is technically
demanding, and biopsy samples do not necessarily represent
the entire cancer cell population, detection of T790M in
plasma DNA has considerable clinical benefits. A recent study
reported discordant genotypes between tumor biopsy and
blood-based analyses.(22) As shown earlier, therapies with cyto-
toxic agents may suppress the T790M ctDNA. It did not
appear before the onset of acquired resistance either. Thus, the
timing of sampling should be precisely determined. Detection
of T790M is among the most intensively studied in this field,
and applications of various technologies are reported.(11,18,23,24)
Because quantitative approaches may not be necessary for this
purpose, evaluation of various technologies might be benefi-
cial.
The present study clearly establishes the correlation
between ctDNA dynamics and disease progression ⁄ response
to EGFR-TKI. However, for clinical applications, prospective
studies are essential. In particular, detailed descriptions of
responses to various therapies are needed. Moreover, the
findings on the T790M ctDNA need confirmation with addi-
tional samples.
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Additional supporting information may be found in the online version of this article:
Fig. S1. Circulating tumor DNA dynamics in the course of epidermal growth factor receptor tyrosine kinase inhibitor treatment. These patients are
not shown in Fig. 2.
Table S1. Patient information for cases in Figs 2,S1.
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